Cognition and memory loss do not demonstrate adverse effects with evolocumab and statin therapy.
Dr. Roger McIntyre suggests that the clinical relevance of cognitive dysfunction for any individual patient can only be adjudicated on a case-by-case basis.
Dysfunction across several cognitive domains is often concomitant with depression.
Most aging humans will develop some degree of decline in cognitive capacity.
Investigators used fMRI to examine whether disruption of long-term fear memory reconsolidation can attenuate the activity in the amygdala at re-exposure to fear cues.
Tetrahydrocannabinol (THC) is the main active chemical ingredient found in cannabis and is a potent cannabinoid receptor (CB)-1 agonist.
The memory-enhancing effects of methylene blue have previously been associated with improvement of memory consolidation.
The current findings are in line with previous studies reporting beneficial effects of physical exercise on memory acquisition, consolidation, reconsolidation, and retrieval.
Study participants with moderate to severe anxiety exhibited poor visual and verbal memory.
While scientists have long known that tau is involved in dementia, the way in which it hinders cognitive function has remained uncertain.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Cannabis Use in Adolescence Associated With Poorer Mental Health Outcomes
- Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia
- Insomnia in Borderline Personality Disorder May Increase Suicide Risk
- FDA Approves Powerful New Opioid Despite Criticisms
- The Challenges of Identifying Biomarkers of Psychiatric Illness
- Heart Rate Variability Predicts Treatment Response in Anxious Depression
- Impulsivity in Bipolar Disorder, Borderline Personality Disorder, ADHD
- Psychotropic Medication May Reduce Symptoms and Improve Functioning in PTSD
- Social Decline a Predictor of Conversion Outcome in High-Risk Individuals
- Buprenorphine/Samidorphan Helpful in Refractory Depression